In short: NeoGraft is a powered, operator-controlled device used during follicular unit extraction. It combines a rotating punch with suction. ARTAS is a separate image-guided robotic system, and the device name alone does not prove faster surgery, better growth or lower risk.

A NeoGraft hair transplant is FUE surgery performed with a powered, suction-assisted device during graft removal and, in some descriptions, placement. ARTAS is a separate robotic system, and the NeoGraft name does not establish that the operation will be safer or produce better growth (ISHRS FUE instruments; FUE terminology paper).

The machine changes how certain physical steps can be carried out. Diagnosis, donor planning, hairline design, consent, recipient-site creation and clinical follow-up still need accountable people with the right training and legal scope (ISHRS qualifications statement). GetHair can arrange a consultation with a partner clinic, while the clinic assesses you, plans the procedure and performs any surgery.

What is a NeoGraft hair transplant?

NeoGraft is a mechanical FUE instrument. The International Society of Hair Restoration Surgery, or ISHRS, describes a rotating sharp punch that cuts around a follicular unit and suction that moves the freed graft to a collection tray. The device works within hair-transplant surgery and does not create new follicles (ISHRS FUE instruments).

FUE refers to removing follicular units individually from a donor area. The NHS describes individual grafts being removed one by one and then placed into small cuts in the recipient area. It also notes that FUE leaves many small scars, even when they may be hard to see (NHS hair transplant guidance). A powered punch or suction system does not make those incisions disappear.

A 2013 ISHRS terminology paper gives a more technical, historical description. It records a motorised rotating handpiece, negative pressure to draw a loosened graft into a chamber and positive pressure that could be used during insertion. It also says grafts could be removed with forceps. The paper standardises technical language and describes the device as it was documented then. It does not establish current availability, current regulatory labelling or a clinical advantage (FUE terminology paper).

Clinic language can blur the line between the device and the whole operation. Ask which NeoGraft component and workflow the clinic means, which stages use it and which stages use other instruments. The answer should cover harvesting, graft handling, recipient-site creation and placement separately (FUE terminology paper).

How does the workflow divide between device and team?

During harvesting, an operator aligns the punch with a follicular unit, incises around it and uses suction or forceps after the graft has been loosened. The collection step does not select a suitable patient, decide how much donor hair can be used or design the recipient area. Those decisions sit outside the device description in the ISHRS sources (ISHRS FUE instruments; FUE terminology paper).

After extraction, a clinic must inspect and handle grafts, create recipient sites with a planned direction and distribution, place the grafts, monitor the patient and provide aftercare. Suction can be one part of that workflow without controlling every surgical stage (NHS hair transplant guidance; ISHRS qualifications statement).

The ISHRS position statement treats donor harvesting, hairline design and recipient-site creation as surgical work. It says those stages should be carried out by a properly trained and licensed physician. Its position also recognises that some countries allow accredited health professionals to perform medical or surgical work within their licence and under the supervision of a licensed physician who is competent in hair surgery (ISHRS qualifications statement).

Ask who examines you, who chooses the punch settings, who makes each incision, who handles and places the grafts, and who can respond to an adverse reaction. The clinic should explain how local law and professional scope apply to each person.

How is NeoGraft different from ARTAS?

NeoGraft and ARTAS belong to different equipment categories in the ISHRS instrument guide. NeoGraft is described as a mechanical device with a rotating punch and suction. ARTAS is described as a computer-assisted, image-guided robotic arm operated by a physician. NeoGraft’s powered handpiece remains a different category from the ARTAS robotic arm (ISHRS FUE instruments).

An ARTAS study tells you nothing certain about NeoGraft performance, while a claim about suction says nothing about image-guided target selection. Even two clinics using the same named device may differ in patient selection, settings, staff roles, graft handling, recipient-site design and aftercare.

Compare tasks rather than labels. Ask whether the equipment rotates or oscillates a punch, how the operator aligns it, how incision depth is controlled, how grafts leave the donor site, where they are held, and how they are placed. Then ask who controls each step and what happens if the planned device cannot be used.

Clearance, approval, registration and a manufacturer’s intended-use statement do not measure hair growth, recovery time or complication rates. This article makes no claim about current NeoGraft clearance, UK availability or a current labelled population because the sources cited here do not establish those facts.

What does the evidence let you conclude?

The cited ISHRS material supports a limited conclusion: NeoGraft combines powered rotation with pressure-assisted graft handling in an FUE workflow. It helps define the mechanism and separate the device from ARTAS. The material contains no controlled comparison of NeoGraft graft survival, final density, healing time, scarring or patient satisfaction (ISHRS FUE instruments; FUE terminology paper).

Suction moves a loosened graft into a chamber, and a powered punch makes the incision around it. The sources cited here do not connect those mechanisms to less graft damage, a shorter operation or a reduced need for skill (FUE terminology paper).

If a clinic makes a comparative claim, ask for evidence on the same device version, patient group, operator role and outcome. Check whether the evidence measures a technical endpoint, such as extraction time or visible graft damage, or a patient outcome, such as growth assessed after suitable follow-up. A clinic’s own case photographs can help you discuss design, but they do not provide a controlled comparison.

Method choice follows assessment. The NHS advises asking why a particular transplant type is recommended, how much relevant experience the surgeon has, how often complications have occurred and what follow-up is available if something goes wrong (NHS hair transplant guidance). A device brand cannot answer those questions.

Risks and what can go wrong

NeoGraft-assisted FUE remains surgery. The NHS lists bleeding, infection and an allergic reaction to anaesthetic among general hair-transplant risks. Grafts may fail to take, noticeable scars can form and surrounding hair can continue to thin. It advises contacting the treating clinic promptly for severe pain or unexpected symptoms (NHS hair transplant guidance).

Device use adds questions about execution rather than removing those baseline risks. Poor punch alignment or depth can damage follicles or surrounding tissue. Taking too much from a donor area can leave visible thinning. Mishandling between extraction and placement may also affect graft condition. The ISHRS sources describe the instrument and professional responsibilities, but they do not supply a dependable NeoGraft complication rate (FUE terminology paper; ISHRS qualifications statement).

If surgery is abroad, settle the route for records, follow-up and complications before booking. NHS guidance says to consider communication between overseas and UK staff, arrangements for aftercare at home, the complaints route and specialist insurance because ordinary travel policies may exclude planned treatment (NHS medical treatment abroad). The NHS overview on going abroad for treatment also advises comprehensive travel insurance.

GetHair arranges consultations, travel and aftercare contact. The partner clinic remains responsible for assessment, consent, surgery and clinical aftercare. Confirm who provides urgent clinical advice once you are home and what an in-person review would involve.

Questions to ask the clinic

Talk it through

GetHair can arrange a free consultation with a partner clinic. The clinic can assess your hair loss, map each stage to the person and device responsible, and explain why its proposed method fits the surgical plan.

Sources